Media Release

For Immediate Release

24 October 2022

National Bioproducts Institute and Imperial's Market Access Healthcare business announce partnership for **Africa**

Pinetown, South Africa - National Bioproducts Institute NPC (NBI) and Imperial's Market Access Healthcare business have entered into a partnership that will make plasma-derived medicinal products (PDMPs) available to patients in seven countries across Africa. During establishment of the partnership, both companies evaluated PMDPs appropriate for the African continent in terms of disease/disorder burden. This landmark agreement aims to increase the availability of lifesaving medicines to patients in these countries and include products that are essential in surgical and critical care settings for the treatment of extensive burns, protein replacement and fluid resuscitation, as well as for Rhesus incompatibility that may occur in pregnant women.

Rhesus incompatibility can result in Haemolytic Disease of the Foetus and Newborn (HDFN), a severe condition responsible for foetal or neonatal death or severe jaundice with ensuing brain damage. The global burden of HDFN is disproportionately high for low- and middle-income countries, such as those in the Sub-Saharan African region, where it is still considered to be a major public health concern, due to the absence or inconsistent application of sophisticated Rhesus-prophylaxis programmes.

"Burns have been identified by the World Health Organization as a global public health concern, with an estimated 180 000 deaths annually, and the vast majority occurring in low- and middle-income countries such as those in the WHO-African region. To be a part of improving the access and availability of life-saving medicines in Africa through this partnership is both essential and extremely valuable for African communities and countries at large", said Mr. David Stubbings, CEO of NBI.

NBI and Imperial aim to grow this partnership in an effort to service more patients across the continent.

"Imperial is excited about this partnership given our leading position in African healthcare supply chain management. This partnership will increase patient access to vital life-saving medicines across the continent, leveraging Imperial's extensive network and experience across all healthcare supply chain channels in Africa. Partnering with NBI is well-aligned with our Market Access strategy of increasing our relevance in existing industries, and specifically speaks to our generic pharmaceutical and backward integration strategic focus areas", says Johan Truter, CEO of Imperial's Market Access business.

Issued by: **Shanay Singh**

> **Head of Business Development National Bioproducts Institute** Shanay.singh@nbisa.org.za

+27 (31) 714 6768

NBI is a Non Profit Company committed to providing safe, cost effective, quality products

About National Bioproducts Institute

National Bioproducts institute (NBI) is a private, non-profit, pharmaceutical manufacturer of human plasma-derived medicinal products. The company's manufacturing site and head office are located in Pinetown, KwaZulu-Natal, South Africa.

NBI's range of pharmaceutical products includes clotting factors, immunoglobulins, albumin solutions and solvent detergent treated dried plasma. NBI's comprehensive range of plasma-derived medicinal products are registered with the South African Health Products Regulatory Authority. Several of NBI's products are listed in the South African Essential Medicines List as well as the World Health Organisation's Essential Drug List. NBI's Pharmaceutical products can be found in 6 countries across Africa. The Biotechnology department within the company develops and manufactures diagnostic kits and monoclonal antibodies for the South African and international diagnostic market. For more information: www.nbisa.org.za

About Imperial

Imperial is an African focused provider of integrated market access and logistics solutions. With a focus on the following key industries - healthcare, consumer, automotive, chemicals, industrial and commodities - we take our clients' and principals' products to some of the fastest growing and most challenging markets in the world. As a leading global logistics provider, we seek out and leverage new technology to deliver innovative, end-to-end solutions. Through our significant African footprint and international expertise, and with the support of our 25,000 people, Imperial's purpose is to connect Africa and the world - and to improve people's lives with access to quality products and services. Imperial became a wholly owned business of DP World in March 2022. For more information: www.imperiallogistics.com

Imperial's Logistics Africa business is the leading logistics supplier in South Africa, and one of the largest on the African continent, providing Contract Logistics, Road Freight and Lead Logistics Provider solutions. The Logistics International business at Imperial has its headquarters in Duisburg, Germany and is responsible for all Group logistics activities (including Contract Logistics and Freight) outside of Africa. Imperial's Market Access business builds complex route-to market solutions that provide principals access to patients and consumers across Africa through comprehensive channel strategies that integrate sourcing, sales, demand generation, distribution, marketing and promotions.